The Pharma Data

APRIL 14, 2021

government for its neutralizing antibody therapies authorized for emergency use as a treatment for COVID-19. who require oxygen therapy due to COVID-19, OR. who require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity.

Government 52

Government Hospitals Long-Term Care Facilities Treatment 52

The Pharma Data

APRIL 16, 2021

who require oxygen therapy due to COVID-19, OR. who require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity. volunteers to evaluate the safety, tolerability, pharmacokinetics and immunogenicity.

Treatment 52

Treatment Hospitals Long-Term Care Facilities Virus 52

The Pharma Data

MAY 4, 2021

INDIANAPOLIS , May 4, 2021 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) is donating COVID-19 therapies to Direct Relief, enabling the humanitarian organization to provide COVID-19 therapies at no cost to low- and lower-middle-income countries most heavily impacted by the pandemic. It is approved in the U.S.

Therapies 52

Therapies Hospitals Treatment FDA Approval 52

The Pharma Data

MARCH 5, 2021

The opinion can now be considered by the EU member states when making decisions on the use of the therapies at a national level before a formal marketing authorization is issued. Lilly Antibody Therapies Around the World. who require oxygen therapy due to COVID-19, OR. Ricks, Lilly’s chairman and CEO.

Treatment 40

Treatment Hospitals Long-Term Care Facilities Therapies 40

The Pharma Data

JANUARY 26, 2021

percent) in patients taking therapy and 36 events (7.0 Bamlanivimab and etesevimab together also demonstrated statistically significant improvements on all key secondary endpoints, providing strong evidence that the therapy reduced viral load and accelerated symptom resolution. who require oxygen therapy due to COVID-19, OR.

Hospitals 52

Hospitals Treatment Trials Long-Term Care Facilities 52

The Pharma Data

MARCH 11, 2021

This new Phase 3 cohort of BLAZE-1 included 769 high-risk patients, aged 12 and older with mild to moderate COVID-19 (therapy: n=511; placebo: n=258). who require oxygen therapy due to COVID-19, OR. volunteers to evaluate the safety, tolerability, pharmacokinetics and immunogenicity.

Hospitals 40

Hospitals Trials Long-Term Care Facilities Treatment 40